Ran Wang | Pulmonary Hypertension | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Ran Wang | Pulmonary Hypertension | Best Researcher Award

First Affiliated Hospital of Anhui Medical University | China

Dr. Ran Wang is an accomplished respiratory medicine researcher whose work has significantly advanced the understanding of pulmonary hypertension and chronic obstructive pulmonary disease (COPD). With more than two decades of clinical and scientific experience, he has extensively investigated the molecular mechanisms underlying hypoxic pulmonary hypertension and COPD pathogenesis. His research has contributed to improved insights into vascular remodeling, inflammatory signaling, and pulmonary vascular resistance, helping to strengthen the scientific basis for future diagnostic and therapeutic strategies.

He has successfully led multiple high-impact research projects, including two funded by the National Natural Science Foundation and three additional provincial-level studies. His work spans basic, translational, and clinical domains, integrating experimental models with patient-centered research to address key challenges in pulmonary vascular diseases. He has authored or co-authored 59 peer-reviewed journal articles, including over 50 SCI-indexed publications and more than 20 as first or corresponding author. His research outputs include four patents related to respiratory disease mechanisms and clinical application innovations.

In addition to his scholarly publications, he serves on editorial boards of leading journals such as Journal of Cancer Research and Clinical Oncology, BMC Pulmonary Medicine, and Cancer Control, contributing to the advancement of scientific discourse in respiratory and cancer research.

Profile: Scopus

Featured Publications:

  • Han, R., Guan, Y., Li, P., Tang, M., Fei, G., Zeng, D., & Wang, R. (2025). Real-world efficacy of oral azvudine in hospitalized patients with COVID-19: A multicenter retrospective cohort study. Journal of Infection and Public Health, 18(12), 102987.

  • Liu, Y., Wang, R., & Jiang, T. (2025). RNA-binding proteins as a molecular link between COPD and pulmonary hypertension. International Journal of Medical Sciences, 22(8), 1979–1991.

  • Rao, B., Wang, D., Yang, M., … et al. (2025). Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: A multicenter, retrospective, cohort study. BMC Infectious Diseases, 25, 275.

 

 

 

Ann-Kathrin Eisfeld | Molecular Profiles | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Ann-Kathrin Eisfeld | Molecular Profiles | Best Researcher Award

The Ohio State University | United States

Dr. Ann-Kathrin Eisfeld is an internationally recognized physician-scientist and Associate Professor with Tenure in the Division of Hematology at The Ohio State University, where she also serves as Director of the Clara D. Bloomfield Center for Leukemia Outcomes Research. Her research focuses on the molecular and genetic underpinnings of acute myeloid leukemia (AML), with a particular emphasis on translational applications that improve patient outcomes. Dr. Eisfeld has published extensively in high-impact journals such as Nature, Leukemia, Blood, and Cell Stem Cell, contributing significantly to our understanding of leukemia biology, clonal evolution, and treatment resistance. she has authored over 100 peer-reviewed scientific publications, with an h-index of 38, more than 6,500 citations, and has led or co-led multiple collaborative studies within national consortia such as the Alliance for Clinical Trials in Oncology. Her work has identified critical biomarkers and therapeutic targets in AML, including insights into TP53 mutations, FLT3 alterations, and resistance mechanisms to venetoclax. Recognized for her integration of clinical insight with cutting-edge genomics, Dr. Eisfeld is a leading voice in precision oncology and leukemia research, shaping the future of individualized treatment strategies through both clinical innovation and scientific discovery.

Profile: Scopus

Featured Publications:

“Highly elevated serum hepcidin in patients with acute myeloid leukemia prior to and after allogeneic hematopoietic cell transplantation: Does this protect from excessive parenchymal iron loading?”

“Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia”

“miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia”

“Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia”

“Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation”

“inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations”

“Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients”

“In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline”

“A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia”